I disagree with you on that. It already has been a long term bottom shelf stock. They have made considerable changes to their strategy which I believe is on the forefront of being realised as a profitable venture.
The upcoming assay results should be more than encouraging enough to at least double this ridiculously low market cap. Remember they pulled 16g/t gold from the sampling program!
I am also expecting some more sensitive news regarding the hydro venture in the near future.
There is a reason heavy investment was made at 2c. A stellar bargain to be offered that to retail buyers right now. Incredible opportunity for the patient.
Add to My Watchlist
What is My Watchlist?
